| Written | 1997-10 | Christine Pérot, Jean-Loup Huret |
| - | ||
| Updated | 1998-12 | Christine Pérot, Jean-Loup Huret |
| Laboratoire de Cytogenetique, Hopital Saint-Antoine, Paris, France | ||
| Updated | 2014-10 | Thomas Smol, Marie-Agnès Collonge-Rame |
| Laboratoire de Cytogenetique, Hopital Saint-Antoine, Paris, France |
| Identity |
| ICD-Topo | C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS |
| ICD-Morpho | 9837/3 T lymphoblastic leukaemia/lymphoma |
| ICD-Morpho | 9861/3 AML with mutated NPM1; AML with mutated CEBPA; Acute myeloid leukaemia, NOS |
| Atlas_Id | 1018 |
 | |
| t(8;16)(p11;p13) G- banding (left) - Courtesy Thomas Smol and Marie-Agnès Collonge-Rame (top), Jean-Luc Lai (second row) and Charles D. Bangs (third and bottom row), R- banding (right) - Courtesy Thomas Smol and Marie-Agnès Collonge-Rame (top) and Jean-Luc Lai (second row), and ideogram (bottom right) - Courtesy Charles D. Bangs. | |
| Clinics and Pathology |
| Disease | Acute myeloid leukemia (AML) including AML-M4, AML-M5a/M5b; Treatment related AML (t-AML). |
| Note | In t-AML with t(8;16), patients often had a previous history of solid tumour ( |
| Phenotype / cell stem origin | AML with t(8;16) may arise from an early stem cell with myeloid and monoblastic differentiation potential. |
| Epidemiology | Rare disease: a hundred and twenty cases have been reported in Mitelman database; (<1% of AML); found in children (median age at diagnosis: 1.2 years) and adults (median age at diagnosis: 59.4 years) with a female predominance (2/3). |
| Clinics | Disseminated intra vascular coagulation may be present; extramedullary infiltration; 20% of the cases could be therapy-related. |
| Cytology | Blast cells present a myelomonocytic stage of differentiation, and are characterized by a phenomenon of erythrophagocytosis with strong peroxidase and esterase activities. Immunophenotyping reveals CD4, CD14, CD13, CD33, CD56 and HLA-DR positives; CD34, CD117 and CD133 negatives. |
 | |
| The t(8;16) has been cloned and shown to fuse the MOZ (monocytic leukemia zinc finger) gene at 8p11.2 to the CBP (CREB binding protein) gene at 16p13.3. The MOZ gene has also been found to be involved in variant translocations t(8;19)(p11;q13) and t(8;22)(p11;q13) and inv(8)(p11q13) translocations associated with M5/M4 AML.This translocation is associated with AML M5/M4. In the majority of cases it is associated with features of hemophagocytosis by leukemic cells, particularly erythrophagocytosis - Text and iconography Courtesy Georges Flandrin 2001. | |
| Prognosis | The prognosis is poor. In published series, death of patients occurs in half of the cases during the first 10 months after diagnosis due to infections or bleeding; survival is often less than 1 year but spontaneous remission has occurred (at least) once. |
| Cytogenetics |
 | |
| t(8;16)(p11;p13) : FISH with BAC KAT6A RP11-313J18 (8p11-21) probe (Amplitech) in red and BAC RP11-489O1 (16p13.11) probe (Amplitech) in green - Courtesy Thomas Smol and Marie-Agnès Collonge-Rame. | |
| Additional anomalies | Sole anomaly in 53.3% of cases; in 23.3% of cases, single additional abnormality: +8 ,various; in 23.3% of cases: complex karyotype; rare chromosome 7 abnormalities, often in t-AML. |
| Variants | Complex variant t(8;16;V) may occur and has been described on rare occasions. 8p11 may have other partners: t(8;22)(p11;q13) which involve EP300 in 22q13, EP300 is a homologue of CREBBP with acetyltransferase activity; t(8;19)(p11;q13.3) which should involve LEUTX on 19q13 (found in one t-AML case); inv(8)(p11p13) which leads to MYST3- NCOA2 fusion; t(8;20)(p11;q13) leading to MYST3- NCOA3 fusion. |
| Genes involved and Proteins |
| Gene Name | KAT6A (MYST histone acetyltransferase (monocytic leukemia) 3 |
| Location | 8p11.21 |
| Note | KAT6A is also known as MYST3, or MOZ (monocytic leukemia zinc finger). |
| Dna / Rna | KAT6A gene is composed of 17 exons, with a MYST domain, located in exons 9-14, that remains intact in the t(8;16) translocations. |
| Protein | KAT6A gene encodes for a nuclear protein with histone acetyltransferase (HAT) due to MYST domain, and transcriptional regulator activities. |
| Gene Name | CREBBP (CREB binding protein) |
| Location | 16p13.3 |
| Note | CREBBP is also known as CBP. |
| Dna / Rna | CREBBP is composed of 31 exons. |
| Protein | The protein encoded shows intrinsic histone acetyltransferase activity and shares regions of very high sequence similarity with protein p300. |
| Result of the chromosomal anomaly |
| Blue boxes represent exons of KAT6A gene and orange boxes represent exons of CREBBP gene (diagram is not to scale). | |
 | |
| Description | 5' KAT6A - 3' CREBBP or 5' CREBBP - 3' KAT6A. |
| Transcript | TRANSCRIPT Five KAT6A -CREBBP transcripts have been descripted: type I (KAT6A exon 16 - CREBBP exon 3); type II (KAT6A exon 16 - CREBBP exon 4); type III (KAT6A exon 17 - CREBBP exon 2 or 4); type IV (KAT6A exon 15 - CREBBP exon 4); type V (KAT6A exon 15 - CREBBP exon 5). Type I transcript is the most frequent fusion product. Reciprocal transcripts CREBBP- KAT6A: type I (CREBBP exon 2 - KAT6A exon 17); type IV (CREBBP exon 3 - KAT6A exon 16) are also found. |
 | |
| H1/5: Histone H1/5-like; ZF: zinc finger domain; HAT: Histone Acetyltransferase; S: serine-rich domain; QP: glutamine and proline-rich domain; M: methionine-rich domain; RID: receptor-interacting domain; CH1-2-3: cysteine and histidine-rich domain; KIX: binding site of CREB; Bd: bromodomain; Q: glutamine-rich domain. | |
| Description | The breakpoint for KAT6A is amino acid 1.013 or amino acid 1.117 (in the acidic domain). Fusion protein loses part of acidic domain in C-terminal. HAT domains in KAT6A and CREBBP are conserved. |
| Oncogenesis | t(8;16) AML are characterized by overexpression of HOXA9, HOXA10, and MEIS1; upregulation of RET and PRL; downregulation of CCND2, STAT5 and WT1. They share similarities with MLL-rearranged leukemias suggesting a partially common leukemogenic pathway. |
| Bibliography |
| The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. |
| Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm FG, Chaganti RS, Civin CI, Disteche C, Dubé I, Frischauf AM, Horsman D, Mitelman F, Volinia S, Watmore AE, Housman DE |
| Nature genetics. 1996 ; 14 (1) : 33-41. |
| PMID 8782817 |
| The 8p11 anomaly in monoblastic leukaemia. |
| Brizard A, Guilhot F, Huret JL, Benz-Lemoine E, Tanzer J |
| Leukemia research. 1988 ; 12 (8) : 693-697. |
| PMID 3184987 |
| Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. |
| Camós M, Esteve J, Jares P, Colomer D, Rozman M, Villamor N, Costa D, Carrió A, Nomdedéu J, Montserrat E, Campo E. |
| Cancer Res. 2006; 66(14): 6947-54. |
| PMID 16849538 |
| The leucine twenty homeobox (LEUTX) gene, which lacks a histone acetyltransferase domain, is fused to KAT6A in therapy-related acute myeloid leukemia with t(8;19)(p11;q13). |
| Chinen Y1, Taki T, Tsutsumi Y, Kobayashi S, Matsumoto Y, Sakamoto N, Kuroda J, Horiike S, Nishida K, Ohno H, Uike N, Taniwaki M. |
| Genes Chromosomes Cancer. 2014; 53(4): 299-308. |
| PMID 24446090 |
| Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group. |
| Coenen EA, Zwaan CM, Reinhardt D, Harrison CJ, Haas OA, de Haas V, Mihál V, De Moerloose B, Jeison M, Rubnitz JE, Tomizawa D, Johnston D, Alonzo TA, Hasle H, Auvrignon A, Dworzak M, Pession A, van der Velden VH, Swansbury J, Wong KF, Terui K, Savasan S, Winstanley M, Vaitkeviciene G, Zimmermann M, Pieters R, van den Heuvel-Eibrink MM. |
| Blood. 2013; 122(15): 2704-13. |
| PMID 23974201 |
| Acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene. |
| Dèaz-Beyá M, Navarro A, Ferrer G, Dèaz T, Gel B, Camós M, Pratcorona M, Torrebadell M, Rozman M, Colomer D, Monzo M, Esteve J. |
| Leukemia. 2013; 27(3): 595-603. |
| PMID 23022987 |
| Spontaneous remission of congenital leukemia. |
| Dinulos JG, Hawkins DS, Clark BS, Francis JS |
| The Journal of pediatrics. 1997 ; 131 (2) : 300-303. |
| PMID 9290620 |
| Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique. |
| Gervais C, Murati A, Helias C, Struski S, Eischen A, Lippert E, Tigaud I, Penther D, Bastard C, Mugneret F, Poppe B, Speleman F, Talmant P, VanDen Akker J, Baranger L, Barin C, Luquet I, Nadal N, Nguyen-Khac F, Maarek O, Herens C, Sainty D, Flandrin G, Birnbaum D, Mozziconacci MJ, Lessard M; Groupe Français de Cytogénétique Hématologique (GFCH). |
| Leukemia. 2008; 22(8): 1567-75. |
| PMID 18528428 |
| AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. |
| Haferlach T, Kohlmann A, Klein HU, Ruckert C, Dugas M, Williams PM, Kern W, Schnittger S, Bacher U, Löffler H, Haferlach C. |
| Leukemia. 2009; 23(5): 934-43. |
| PMID 19194466 |
| Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. |
| Quesnel B, Kantarjian H, Bjergaard JP, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 ; 11 (12) : 2370-2379. |
| PMID 8246025 |
| Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. |
| Rozman M, Camós M, Colomer D, Villamor N, Esteve J, Costa D, Carrió A, Aymerich M, Aguilar JL, Domingo A, Solé F, Gomis F, Florensa L, Montserrat E, Campo E. |
| Genes Chromosomes Cancer. 2004; 40(2): 140-5. |
| PMID 15101047 |
| RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications. |
| Schmidt HH, Strehl S, Thaler D, Strunk D, Sill H, Linkesch W, Jäger U, Sperr W, Greinix HT, König M, Emberger W, Haas OA. |
| Leukemia. 2004; 18(6): 1115-21. |
| PMID 15085163 |
| A distinct subtype of M4/M5 acute myeloblastic leukemia (AML) associated with t(8:16)(p11:p13), in a patient with the variant t(8:19)(p11:q13)--case report and review of the literature. |
| Stark B, Resnitzky P, Jeison M, Luria D, Blau O, Avigad S, Shaft D, Kodman Y, Gobuzov R, Ash S |
| Leukemia research. 1995 ; 19 (6) : 367-379. |
| PMID 7596149 |
| Translocation t(8;16)(p11;p13) in acute non-lymphocytic leukemia: report on two new cases and review of the literature. |
| Velloso ER, Mecucci C, Michaux L, Van Orshoven A, Stul M, Boogaerts M, Bosly A, Cassiman JJ, Van Den Berghe H |
| Leukemia & lymphoma. 1996 ; 21 (1-2) : 137-142. |
| PMID 8907281 |
| Citation |
| This paper should be referenced as such : |
| Smol T, Collonge-Rame MA |
| t(8;16)(p11;p13) KAT6A/CREBBP; |
| Atlas Genet Cytogenet Oncol Haematol. in press |
| On line version : http://AtlasGeneticsOncology.org/Anomalies/t0816ID1018.html |
| History of this paper: |
| Pérot, C, Huret, JL. t(8;16)(p11;p13). Atlas Genet Cytogenet Oncol Haematol. 1997;1(2):79-80. |
| http://documents.irevues.inist.fr/bitstream/handle/2042/32062/10-1997-t0816ID1018.pdf |
| Pérot, C, Huret, JL. t(8;16)(p11;p13). Atlas Genet Cytogenet Oncol Haematol. 1999;3(1):36-38. |
| http://documents.irevues.inist.fr/bitstream/handle/2042/37488/12-1998-t0816.pdf |
| Thomas Smol, Marie-Agns Collonge-Rame. t(8;16)(p11;p13) KAT6A/CREBBP. Atlas Genet Cytogenet Oncol Haematol. 2015;19(7):476-480. |
| http://documents.irevues.inist.fr/bitstream/handle/2042/62192/10-2014-t0816ID1018.pdf |
| Translocations implicated (Data extracted from papers in the Atlas) |
| t(8;16)(p11;p13) KAT6A/CREBBP | |
| External links |
| REVIEW articles | automatic search in PubMed |
| Last year articles | automatic search in PubMed |
| All articles | automatic search in PubMed |
| © Atlas of Genetics and Cytogenetics in Oncology and Haematology | indexed on : Wed Feb 19 18:20:08 CET 2020 |
For comments and suggestions or contributions, please contact us